Larimar Therapeutics (LRMR)
(Delayed Data from NSDQ)
$7.89 USD
+0.62 (8.53%)
Updated May 21, 2024 04:00 PM ET
4-Sell of 5 4
D Value F Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
LRMR 7.89 +0.62(8.53%)
Will LRMR be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for LRMR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LRMR
Nektar Therapeutics (NKTR) Q1 Earnings & Revenues Beat
Larimar (LRMR) Upgraded to Strong Buy: What Does It Mean for the Stock?
LRMR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Theravance's (TBPH) Q1 Earnings and Revenues Miss Estimates
New Strong Buy Stocks for May 9th
United Therapeutics (UTHR) Q1 Earnings Beat, Sales Miss
Other News for LRMR
Larimar Therapeutics price target raised by $4 at Citi, here's why
Why James Hardie Industries Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Buy Rating Reaffirmed for Larimar Therapeutics Post FDA Clinical Hold Lift and Positive Drug Trial Trajectory
Larimar clinical hold lift 'very positive for the stock,' says Leerink
Larimar clinical hold removal 'nice surprise,' says William Blair